Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants

Translational Research

Volumn 158, Issue 2, 2011, Pages 99-105

  Tsai, Alexander K ^a   Steffen, Brian T ^a   Ordovas, Jose M ^b,c   Straka, Robert ^d   Zhou, Xia ^d   Hanson, Naomi Q ^a   Arnett, Donna ^e   Tsai, Michael Y ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY   (United States)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; FENOFIBRATE; SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY;

EID: 79960316123     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2011.01.014     Document Type: Article

References (42)

1. M.J. Caslake, C.J. Packard, and K.E. Suckling Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease Atherosclerosis 150 2000 413 419 (Pubitemid 30336554)
2. C.H. MacPhee, K.E. Moores, and H.F. Boyd Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor Biochem J 338 1999 479 487
3. T. Münzel, and T. Gori Lipoprotein-associated phospholipase A(2), a marker of vascular inflammation and systemic vulnerability Eur Heart J 30 2009 2829 2831
4. A. Thompson, P. Gao, and L. Orfei with Lp-PLA(2) Studies Collaboration. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet 375 2010 1536 1544
5. K. Sudhir Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction Vasc Health Risk Manag 2 2006 153 156 (Pubitemid 43853429)
6. N. Kume, M.I. Cybulsky, and M.A. Gimbrone Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells J Clin Invest 90 1992 1138 1144
7. B.V. Khan, S.S. Parthasarathy, R.W. Alexander, and R.M. Medford Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells J Clin Invest 95 1995 1262 1270
8. R.S. Rosenson Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome Am Heart J 155 2008 499
9. V.G. Saougos, A.P. Tambaki, and M. Kalogirou Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2 Arterioscler Thromb Vasc Biol 27 2007 2236 2243 (Pubitemid 350287255)
10. T.D. Filippatos, E.N. Liberopoulos, and M. Kostapanos The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome Diabetes Obes Metab 10 2008 476 483 (Pubitemid 351639090)
11. V. Tsimihodimos, A. Kostoula, and A. Kakafika Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values J Cardiovasc Pharmacol Ther 9 2004 27 33 (Pubitemid 38525755)
12. A. Hiukka, J. Westerbacka, and E.S. Leinonen Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus J Am Coll Cardiol 52 2008 2190 2197
13. K. Empen, R.J. Frost, H.C. Geiss, C. Otto, and K.G. Parhofer Differential effects of fenofibrate versus atorvastatin on the concentrations of E-selectin and vascular cellular adhesion molecule-1 in patients with type 2 diabetes mellitus and mixed hyperlipoproteinemia: a randomized cross-over trial Cardiovasc Diabetol 2 2003 17
14. R. Belfort, R. Berria, J. Cornell, and K. Cusi Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome J Clin Endocrinol Metab 95 2010 829 836
15. K.E. Ryan, D.R. McCance, L. Powell, R. McMahon, and E.R. Trimble Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men Atherosclerosis 194 2007 e123 e130
16. W.Y. Wang, J. Li, and D. Yang OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways Cardiovasc Res 85 2010 845 852
17. C.Q. Lai, D.K. Arnett, and D. Corella Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study Arterioscler Thromb Vasc Biol 27 2007 1417 1425 (Pubitemid 46809433)
18. S.J. Robins, D. Collins, and J.T. Wittes Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591 (Pubitemid 32240250)
19. A. Keech, R.J. Simes, and P. Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
20. J.C. Fruchart, F.M. Sacks, and M.P. Hermans Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i) Curr Med Res Opin 26 2010 1793 1797
21. C.J. Packard, D.S. O'Reilly, and M.J. Caslake Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group N Engl J Med 343 2000 1148 1155
22. C.A. Garza, V.M. Montori, and J.P. McConnell Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review Mayo Clin Proc 82 2007 159 165 (Pubitemid 46198473)
23. M.H. Davidson, M.A. Corson, and M.J. Alberts Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines Am J Cardiol 101 2008 51F 57F
24. S.A. Karabina, T.A. Liapikos, G. Grekas, J. Goudevenos, and A.D. Tselepis Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions Biochim Biophys Acta 1213 1994 34 38 (Pubitemid 24204562)
25. M. Farnier, I. Perevozskaya, W.V. Taggart, D. Kush, and Y.B. Mitchel VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate J Lipid Res 49 2008 2641 2647
26. J. Vakkilainen, G. Steiner, J.C. Ansquer, H. Perttunen-Nio, and M.R. Taskinen Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes Diabetes Care 25 2002 627 628
27. I. Tkac, A. Molcanyiova, M. Javorsky, and M. Kozarova Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity Pharmacol Res 53 2006 261 264 (Pubitemid 43247538)
28. W. Phuntuwate, C. Suthisisang, and B. Koanantakul Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels Atherosclerosis 196 2008 122 128
29. Y. Dong, B.T. Steffen, and J. Cao Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants Atherosclerosis 214 2011 422 425
30. K.D. O'Brien, M.D. Allen, and T.O. McDonald Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis J Clin Invest 92 1993 945 951 (Pubitemid 23262418)
31. Y. Huo, and K. Ley Adhesion molecules and atherogenesis Acta Physiol Scand 173 2001 35 43 (Pubitemid 32948331)
32. S. Blankenberg, S. Barbaux, and L. Tiret Adhesion molecules and atherosclerosis Atherosclerosis 170 2003 191 203 (Pubitemid 37377790)
33. A. Papagianni, M. Kalovoulos, and D. Kirmizis Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients Nephrol Dial Transplant 18 2003 113 119 (Pubitemid 36104486)
34. C. Schmidt, J. Hulthe, and B. Fagerberg Baseline ICAM-1 and VCAM-1 are increased in initially healthy middle-aged men who develop cardiovascular disease during 6.6 years of follow-up Angiology 60 2009 108 114
35. S. Ichihara, K. Obata, and Y. Yamada Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors J Mol Cell Cardiol 41 2006 318 329 (Pubitemid 44080222)
36. Y. Rival, N. Benéteau, and T. Taillandier PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells Eur J Pharmacol 435 2002 143 151 (Pubitemid 34131694)
37. C.A. Bursill, M.L. Castro, and D.T. Beattie High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo Arterioscler Thromb Vasc Biol 30 2010 1773 1778
38. K.C. McGrath, X.H. Li, and R. Puranik Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells Arterioscler Thromb Vasc Biol 29 2009 877 882
39. S. Rajan, J. Ye, S. Bai, F. Huang, and Y.L. Guo NF-kappaB, but not p38 MAP kinase, is required for TNF-alpha-induced expression of cell adhesion molecules in endothelial cells J Cell Biochem 105 2008 477 486
40. M. Zerfaoui, Y. Suzuki, and A.S. Naura Nuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: differential requirement for PARP-1 expression and interaction Cell Signal 20 2008 186 194 (Pubitemid 350138380)
41. J.H. Oh, and T.K. Kwon Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells Int Immunopharmacol 9 2009 614 619
42. V. Tsimihodimos, A. Kakafika, and A.P. Tambaki Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins J Lipid Res 44 2003 927 934 (Pubitemid 37279653)